ANGPT2 and neoplasm: Given that TKIs can enhance tumor immunogenicity by modulating the tumor microenvironment through inhibition of vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG2), combining TKIs with ICIs represents a rational strategy to improve treatment efficacy (Fukumura et al., 2018; Huinen et al., 2021).